|Articles|May 1, 2020

Measles Vaccine Coverage Remains Suboptimal in Eastern Mediterranean

Author(s)Jonna Lorenz

Vaccination rates remain below recommended levels in many areas.

Large-scale measles outbreaks in the Eastern Mediterranean region have drawn attention to suboptimal vaccination coverage there, according to the US Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report.

The report highlights the ebb and flow of the disease in the region, which saw cases nearly triple from 2013 to 2018 before declining in 2019. Measles elimination was achieved in 3 of the 21 countries in the Eastern Mediterranean Region (EMR) (Bahrain, Iran and Oman) by the end of 2019, according to the EMR Verification Commission for Measles Elimination, which was established in February 2018.

Still, vaccination rates remain below recommended levels in many areas, and work remains to reach the World Health Organization region’s 1997 goal of eliminating the disease, which was included as a priority in the Eastern Mediterranean Vaccine Action Plan of 2016—2020.

“To accelerate progress toward measles elimination in EMR, the visibility of efforts to achieve the measles elimination goal must be raised, including the benefits of achieving measles elimination,” authors of the report noted.

Strategies to achieve measles elimination include boosting vaccination coverage to ≥95% for first- and second-dose of measles containing vaccine through routine and supplementary vaccination activities, conduct surveillance and provide clinical case management. The vaccination coverage goal of ≥95% was achieved in 11 of the region’s 21 countries in 2018, and only Somalia had yet to introduce the second dose of the vaccine. Supplementary vaccination activities resulted in vaccination of 326.4 million people during 2013-2019.

First-dose coverage increased from 79% in 2013 to 82% in 2018. Second-dose coverage increased from 59% in 2013 to 74% in 2018.

Reported measles cases in the region hit a record low of 9,499 before rising to 21,734 in 2015, 34,286 in 2017 and 64,198 in 2018 and falling to 16,703 in 2019. The number of genotypes detected decreased from 4 in 2013 to 2 in 2019.

Outbreaks in Pakistan, Somalia, and Yemen drove a near tripling of measles cases from 33.5 per 1 million persons in 2013 to 91.2 in 2018, before a significant drop to 23.3 in 2019.

“In several EMR countries, major challenges to implementing measles elimination activities include civil unrest, armed conflict, and unpredictable mass population displacements and resettlements that can disrupt all aspects of planning and implementation of immunization services delivery,” the report noted.

The Eastern Mediterranean Regional Technical Advisory Group on Immunization recommended forming a task force to apply lessons learned from the Global Polio Eradication Initiative, such as mapping areas where vaccinations were missed and developing a plan to deploy resources.

Measles infections resulted in 140,000 deaths worldwide in 2019, placing the disease among the infectious diseases considered by WHO as urgent challenges to address this decade. A comeback of the disease in the United States and abroad placed it among the top outbreaks of the year, with the United States nearly losing its elimination status.


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
FAQ: Ebola Prevention, Treatment and the Chances of a US Outbreak
As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.